Physician Payment Disclosure Under Health Care Reform: Will the Sun Shine?

References

1. 1.↵
   1. Gagnon M-A,
   2. Lexchin J.

   The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 2008; 5(1): e1.

   OpenUrl
2. 2.↵
   1. Donohue JM,
   2. Cevasco M,
   3. Rosenthal MB

   . A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 2007;357:673–81.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   Kaiser Family Foundations. Prescription drug trends. Available from http://www.kff.org/rxdrugs/upload/3057\N08.pdf. Accessed March 10, 2012.
4. 4.↵
   1. Brennan TA,
   2. Rothman DJ,
   3. Blank L,
   4. et al

   . Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 2006;295:429–33.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Liang BA,
   2. Mackey T

   . Confronting conflict: addressing institutional conflicts of interest in academic medical centers. Am J Law Med 2010;36:136–87.

   OpenUrlPubMed
6. 6.↵
   1. Wazana A

   . Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373–80.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   Pew Prescription Project. Fact sheet: regulating industry payments to physicians: identifying & minimizing conflicts of interest. Revised September 12, 2008. Available from http://www.pewhealth.org/uploadedFiles/PHG/Supporting_Items/IB_FS_PPP_Regulating_Industry_Payments.pdf. Accessed March 10, 2012.
8. 8.↵
   Pew Prescription Project. Fact sheet: physician payments sunshine provision in health care reform. Available from http://www.pewhealth.org/uploadedFiles/PHG/Supporting_Items/IB_FS_PPP_ Sunshine-fact-sheet.pdf. Accessed March 10, 2012.
9. 9.↵
   1. Ross JS,
   2. Lackner JE,
   3. Lurie P,
   4. Gross CP,
   5. Wolfe S,
   6. Krumholz HM

   . Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA 2007;297:1216–23.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Mackey TK,
    2. Liang BA

    . Transparency in physician-industry relationships. Pathol Case Rev 2012;17:144–7.

    OpenUrl
11. 11.↵
    1. Orszag PR,
    2. Emanuel EJ

    . Health care reform and cost control. N Engl J Med 2010;363:601–3.

    OpenUrlCrossRefPubMed
12. 12.↵
    Centers for Medicare & Medicaid Services (CMS), HHS. Medicare, Medicaid, Children’s Health Insurance Programs; transparency reports and reporting of physician ownership or investment interests. Final rule. Fed Regist 2013;78:9457–528.

    OpenUrl
13. 13.↵
    Reuters. U.S. HHS says to further delay Sunshine Act rules. November 1, 2011. Available from http://www.reuters.com/article/2011/11/01/us-sunshine- act-rules-idUSTRE7A046L20111101. Accessed March 10, 2012.
14. 14.↵
    1. Wang SS

    . Drug firms’ medical staffs say what salespeople can’t. June 26, 2009. Available from http://online.wsj.com/article_email/SB124597622797657621-lMyQjAxMDI5NDI1NjkyNzY2Wj.html. Accessed March 10, 2012.
15. 15.↵
    1. Rockoff JD

    . Drug reps soften their sales pitches. January 10, 2012. Available from http://online.wsj.com/article/SB10001424052970204331304577142763014776148. html. Accessed March 11, 2012.
16. 16.↵
    1. Sass C,
    2. Albert E

    . The medical science liaison: an A to Z guide. 2nd ed. Sudbury, MA: eBookIt.com; 2012.
17. 17.↵
    1. Liang BA,
    2. Mackey T

    . Direct-to-consumer advertising with interactive internet media: global regulation and public health issues. JAMA 2011;305:824–5.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Liang BA,
    2. Mackey T

    . Reforming direct-to-consumer advertising. Nat Biotechnol 2011;29:397–400.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Liang BA,
    2. Mackey TK

    . Prevalence and global health implications of social media in direct-to-consumer drug advertising. J Med Internet Res 2011; 13: e64.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Kravitz RL,
    2. Epstein RM,
    3. Feldman MD,
    4. et al

    . Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005;293:1995–2002.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Liang BA,
    2. Mackey T

    . Quality and safety in medical care: what does the future hold? Arch Pathol Lab Med 2011;135:1425–31.

    OpenUrlPubMed
22. 22.↵
    American Medical Student Association. AMSA pharmfree: state & federal policy. Available from http://www.pharmfree.org/policy?id=0003#HI4. Accessed December 3, 2012.